Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

Next Previous
Trial Profile

Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs VIS 410 (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Visterra

    • Most Recent Events

    • 04 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 05 Oct 2017 According to a Visterra media release, this study will be intiated in early 2018.
    • 06 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top